Brivaracetam

Brivaracetam is an antiseizure medication belonging to the racetam family and is a close structural analog of levetiracetam, specifically its 4R-propyl derivative. It was created by the pharmaceutical company UCB through a drug-discovery program aimed at finding selective, high-affinity ligands for synaptic vesicle glycoprotein 2A (SV2A), the same target as levetiracetam ^[2]. It is often described as a third-generation antiseizure drug ^[5].

Following positive late-stage clinical trials, brivaracetam was approved in the European Union in January 2016 and by the United States Food and Drug Administration the following month, where it is sold under the brand name Briviact. In the United States it was placed in Schedule V of the Controlled Substances Act, reflecting a low potential for abuse, while in many other countries it is a prescription-only medicine ^[3]. It is approved as an add-on therapy for focal, or partial-onset, seizures in adults and adolescents ^[3].

Across three pivotal phase III trials, adjunctive brivaracetam significantly reduced the frequency of focal-onset seizures compared with placebo, and these benefits appeared to be maintained over years of follow-up in extension studies ^[2][3]. Notably, some patients who had not responded to or tolerated levetiracetam experienced improved seizure control or fewer behavioral side effects after switching to brivaracetam ^[1]. Pharmacokinetic modeling has suggested it could be used as monotherapy without dose changes, and a systematic review of pediatric use supports its role as adjunctive therapy in children with drug-resistant epilepsy ^[4][5].

Brivaracetam is almost completely absorbed after oral dosing and penetrates the brain quickly, and unlike some antiseizure drugs it can be started directly at a maintenance level without slow titration ^[2]. It is available in several forms, including oral tablets, an oral solution, and an intravenous formulation for situations where swallowing is impractical ^[3]. Commonly reported adverse effects include sleepiness, dizziness, and nausea ^[1][3].

Common side effects include drowsiness, dizziness, fatigue, and nausea, and like other antiseizure drugs it carries a warning for mood and behavioral changes including irritability and, rarely, suicidal ideation. It shouldn't be stopped abruptly because of seizure risk, and it interacts with several drugs including carbamazepine and rifampin. Because it's a controlled prescription medication, self-experimentation is a genuinely bad idea.

Rifampin, a potent CYP2C19 inducer, substantially decreases brivaracetam exposure. In a clinical crossover study in healthy subjects, rifampin 600 mg daily for 5 days reduced brivaracetam plasma AUC by 45% following a single 150 mg oral dose, while increasing the hydroxylated metabolite BRV-OH by 109% ^[31]. This reduction in drug concentration may compromise seizure control; patients requiring concurrent rifampin therapy should be monitored closely and may need dose adjustment. Other CYP2C19 enzyme inducers such as phenytoin, carbamazepine, or phenobarbital are expected to produce similar effects on brivaracetam metabolism, though systematic clinical data are limited. Conversely, CYP2C19 inhibitors may elevate brivaracetam levels and warrant dose reduction if added to existing therapy.

Checking a whole stack? Run it through interactions + stacks.